Prasad Kulkarni, Medical Director of the Serum Institute of India, discusses his recent phase 2/3 trial on the Covishield vaccine published in eClinicalMedicine, as well as its implications for COVID vaccine development in general.
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Prasad Kulkarni, Medical Director of the Serum Institute of India, discusses his recent phase 2/3 trial on the Covishield vaccine published in eClinicalMedicine, as well as its implications for COVID vaccine development in general.
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv